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Recently, it was reported that angiopoietin-like pro-
tein 8 (ANGPTL8) was the long-sought ‘‘betatrophin’’
that could control pancreatic beta cell proliferation.
However, studies of Angptl8/ mice revealed pro-
found reduction of triglyceride levels, but no abnor-
malities in glucose homeostasis. We now report
that Angptl8/ mice undergo entirely normal beta
cell expansion in response to insulin resistance re-
sulting from either a high-fat diet or from the admin-
istration of the insulin receptor antagonist S961.
Furthermore, overexpression of ANGPTL8 in livers
of mice doubles plasma triglyceride levels, but
does not alter beta cell expansion nor glucose meta-
bolism. These data indicate that ANGPTL8 does
not play a role in controlling beta cell growth, nor
can it be given to induce such expansion. The find-
ings that plasma triglyceride levels are reduced by
Angptl8 deletion and increased following ANGPTL8
overexpression support the possibility that inhibition
of ANGPTL8 represents a therapeutic strategy for
hypertriglyceridemia.
INTRODUCTION
The pancreatic beta cell possesses the capacity to self-duplicate
(Dor et al., 2004). Insulin resistance elicits a compensatory in-
crease in insulin secretion to maintain normoglycemia. Type 2
diabetes develops when the beta cells cannot compensate for
the increase in insulin requirement. After an initial compensatory
expansion, beta cell function and mass progressively declines
(Butler et al., 2003; Henquin and Rahier, 2011; U.K. Prospective
Diabetes Study Group, 1995; Yoon et al., 2003). The factors that
expand beta cell mass in response to insulin resistance have not
been molecularly defined.
Angiopoietin-like protein 8 (ANGPTL8) is a circulating protein
that is expressed primarily in liver and adipose tissue. Hepatic
overexpression of ANGPTL8 in mice is associated with hypertri-glyceridemia, whereas inactivation of Angptl8 causes a reduc-
tion in plasma triglyceride levels (Quagliarini et al., 2012; Wang
et al., 2013). ANGPTL8 was recently reported to mediate an in-
crease in beta cell proliferation and beta cell mass in mice where
insulin resistance was induced by the insulin receptor antagonist
S961 (Yi et al., 2013). Overexpression of ANGPTL8, which the
authors refer to as betatrophin, induced beta cell proliferation,
expansion of beta cell mass, and led to improved glycemic
control (Yi et al., 2013).
These findings appear to be in conflict with the observation
that Angptl8/ mice fed either a chow or high-fat diet have no
alteration in glucose homeostasis (Wang et al., 2013). In this
study, we used Angptl8/ mice to determine if ANGPTL8 is
required for beta cell expansion in insulin resistant states as
had been previously reported by Yi et al. (2013).
RESULTS
ANGPTL8 Does Not Regulate Beta Cell Function or
Growth in Response to High-Fat Diet-Induced Insulin
Resistance
Mice lacking ANGPTL8 had normal nonfasted plasma glucose
and insulin levels, but only one-third of the circulating triglycer-
ides of wild-type mice (Figures 1A–1C), as reported previously
(Wang et al., 2013). In addition, we confirmed that Angptl8/
mice had normal glycemic control as revealed by an oral
glucose tolerance (Figure 1E) and insulin tolerance tests (Fig-
ure 1F) (Wang et al., 2013). Angptl8/ and wild-type mice
fed a high-fat diet (60% kCal fat) for 8 weeks had a 40% in-
crease in body weight (Figure 1D), which was associated
with impaired glucose tolerance (Figure 1E) and reduced insu-
lin sensitivity (Figure 1F). No differences in the induction of
impaired glucose tolerance or insulin resistance were observed
between wild-type and knock-out mice. Moreover, the in-
crease in beta cell area (stained for insulin in brown) in fat-
fed mice was comparable in Angptl8/ and wild-type mice
(Figures 1G and 1H). These data indicate that ANGPTL8 is
not essential for beta cell number or function under normal
conditions and is not required for the compensatory beta cell
expansion in response to the insulin resistance resulting from
high-fat diet.Cell 159, 691–696, October 23, 2014 ª2014 Elsevier Inc. 691
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Figure 1. A High-Fat Diet Induces Glucose Intolerance and Beta Cell Growth in Angptl8/ and Wild-Type Mice
(A) Nonfasted plasma glucose in male wild-type (WT) and Angptl8/ (KO) mice on chow diet.
(B) Nonfasted plasma insulin in WT and Angptl8/ mice on chow diet.
(C) Plasma triglyceride levels in WT and Angptl8/ mice on chow diet after 18 hr fasting and 6 hr refeeding.
(D) Body weight in WT and Angptl8/ mice on chow diet and following 8 weeks on high-fat diet (HFD).
(E) Glucose tolerance test in WT and Angptl8/ mice on chow and HFD for 7 weeks.
(F) Insulin tolerance test in WT and Angptl8/ mice on chow and HFD for 8 weeks.
(G) Insulin immunohistochemistry (brown) of representative pancreas sections from chow and HFD Angptl8/ and WT mice.
(H) Beta cell area as a percentage of total pancreas area. All groups had five to seven animals. **p < 0.01; ****p < 0.0001. Values are mean ± SEM. The experiment
was repeated and the results were similar.Overexpression of ANGPTL8 Does Not Change Glucose
Tolerance or Beta Cell Area
Hydrodynamic delivery of ANGPTL8 expression construct
to the livers of chow-fed mice resulted in high circulating
ANGPTL8 levels (Figure 2A). Overexpression of ANGPTL8 for
8 days significantly increased plasma triglyceride levels (Fig-692 Cell 159, 691–696, October 23, 2014 ª2014 Elsevier Inc.ure 2B) but had no effect on plasma glucose or insulin con-
centrations (Figures 2C and 2D). Oral glucose tolerance tests
revealed no difference between control and ANGPTL8 over-
expressing mice (Figure 2E). Beta cell area and mass were
similar in control and ANGPTL8 overexpressing mice (Figures
2F and Figure S1 available online). Consistent with the data
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Figure 2. Overexpression of ANGPTL8
Does Not Alter Glucose Tolerance or Beta
Cell Area
(A) Western blot analysis of plasma following
hydrodynamic delivery (HDD) via tail vein injection
of cDNA encoding a C-terminal V5 epitope-tagged
human ANGPTL8. The control animals were in-
jected with empty vector. An anti-V5 antibody was
used for detection of ANGPTL8.
(B) Nonfasted plasma triglyceride levels in mice
injected with control or ANGPTL8DNA before (day
0) and 8 days after HDD.
(C) Nonfasted plasma glucose in mice injected
with control or ANGPTL8 DNA before (day 0) and
8 days after HDD.
(D) Nonfasted plasma insulin in mice injected with
control or ANGPTL8 DNA before (day 0) and
8 days after HDD.
(E) Oral glucose tolerance test inmice injectedwith
control or ANGPTL8 DNA 6 days after HDD.
(F) Beta cell area as a percentage of total pancreas
area in mice injected with control or ANGPTL8
DNA 8 days after HDD. See also Figure S1.
All groups had six to seven animals. ****p < 0.0001.
Values are mean ± SEM. The experiment was
repeated and the results were similar.in Angptl8/ mice, these overexpression data do not support
a role for ANGPTL8 in the regulation of beta cell function
or number but confirm its involvement in triglyceride
metabolism.
Insulin Receptor Antagonist Promotes Glucose
Intolerance and Beta Cell Expansion in Angptl8/ Mice
Infusion of the insulin receptor antagonist S961 (20 nMol/week)
caused a pronounced and sustained increase in plasma glucose
in both Angptl8/ and wild-type mice (Figure 3A). Plasma
insulin levels were increased >6-fold in both Angptl8/ and
wild-type mice (Figure 3B). Circulating triglyceride levels were
unchanged by S961 in both strains of mice (data not shown).
Mice receiving S961 were severely glucose intolerant (Fig-
ure 3C), which was associated with a compensatory doubling
of the beta cell area and mass in both Angptl8/ and wild-
type mice (Figures 3D and S2). These data show that insulin
receptor antagonism causes glucose intolerance and beta
cell expansion by a mechanism that does not depend upon
ANGPTL8.Cell 159, 691–696,DISCUSSION
The main findings of the study are that (1)
ANGPTL8 is not required for beta cell
function or the compensatory beta cell
growth response to insulin resistance,
(2) overexpression of ANGPTL8 does
not increase beta cell area nor improve
glycemic control, and (3) ANGPTL8 regu-
lates plasma triglyceride levels.
Yi et al. (2013) reported that ANGPTL8
is a betatrophin that controls beta cellproliferation in mice treated with the insulin receptor antagonist
S961. A subsequent publication (Jiao et al., 2014) and our data
confirm the findings that administration of S961 causes severe
glucose intolerance and beta cell expansion in mice. However,
the beta cell growth response was similar in Angptl8/ and
wild-typemice. Thus, ANGPTL8 is not required for the expansion
of the beta cell area in response to insulin resistance induced by
the insulin receptor antagonist S961.
It had previously been reported that wild-type and Angptl8/
mice show no difference in glucose homeostasis (Wang et al.,
2013). In the current study, we demonstrate that both wild-type
and Angptl8/ mice can mount a significant and similar expan-
sion of their beta cell area in response to high-fat diet-induced
insulin resistance. The lack of involvement of ANGPTL8 in the
regulation of beta cell function and growth is supported by our
hydrodynamic overexpression studies. Specifically, high circu-
lating levels of ANGPTL8 in this study were associated with an
increase in plasma triglycerides but caused no change in glyce-
mic control or increase in beta cell area. The lack of expansion of
the beta cell area could theoretically be due to simultaneousOctober 23, 2014 ª2014 Elsevier Inc. 693
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Figure 3. The Insulin Receptor Antagonist
S961 Causes Glucose Intolerance and Beta
Cell Growth in Angptl8/ and Wild-Type
Mice
(A) Nonfasted plasma glucose in Angptl8/ and
WT mice continuously treated with the insulin re-
ceptor antagonist S961 (20 nMol/week) or vehicle
for 13 days.
(B) Nonfasted plasma insulin on days 0 and 13 in
Angptl8/ and WT mice treated with S961
(20 nMol/week) or vehicle.
(C) Oral glucose tolerance test in Angptl8/ and
WT mice treated with S961 (20 nMol/week) or
vehicle at day 11 of the study.
(D) Beta cell area as a percentage of total pancreas
area in Angptl8/ and WT mice treated with S961
(20 nMol/week) or vehicle for 13 days. See also
Figure S2.
All groups had seven to ten animals. **p < 0.001;
***p < 0.0005; ****p < 0.0001. Values are
mean ± SEM.increases in replication and apoptosis frequencies. However,
even if this were the case, it would not change our observation
that Angptl8 overexpression did not increase beta cell area, con-
trary to what was reported by Yi et al. (2013).
The factor(s) controlling beta cell growth in this study have not
been identified. Both the insulin receptor antagonist S961 and
the high-fat diet caused hyperglycemia. Persistent high glucose
levels may contribute to the expansion of the beta cell area. This
is supported by accumulating evidence that glucose signaling
plays an important role for expansion of the beta cell mass. In
particular, glucose infusion in rodents stimulates beta cell prolif-
eration (Alonso et al., 2007; Bernard et al., 1998; Bonner-Weir
et al., 1989). Furthermore, mice haploinsufficient for beta cell
glucokinase are unable to increase their beta cell mass in
response to insulin resistance produced by a high-fat diet
(Terauchi et al., 2007), whereas pharmacological activation of
glucokinase stimulates beta cell proliferation (Porat et al.,
2011). Insulin signaling is unlikely to regulate the beta cell growth
because expansion was observed in the presence of the insulin
receptor antagonist S961. Other factors may also contribute to
stimulation of beta cell proliferation. For example, hepatic insulin
resistance was shown to promote a robust increase in beta cell
proliferation, which seems to be mediated by a circulating factor
that acts independent of insulin and glucose (El Ouaamari et al.,
2013; Michael et al., 2000). The identification of the factor(s)
causing the expansion of the beta cell area is subject to active
investigation. However, those factors may differ in mice and
humans. Jiao et al. (2014) showed that S691 administration in-
creases mouse but not human beta cell proliferation.
Studies in humans suggest that ANGPTL8 levels are increased
in patients with type 1 diabetes. However, ANGPTL8 levels do
not correlate with residual C-peptide levels, glucose control, or
insulin requirement, suggesting that ANGPTL8 does not protect
against beta cell destruction (Espes et al., 2014). The role of
ANGPTL8 in type 2 diabetes and obesity remains controversial.
ANGPTL8 levels were found in one study to correlate with type 2
diabetes and body mass index (Fu et al., 2014), whereas another694 Cell 159, 691–696, October 23, 2014 ª2014 Elsevier Inc.study reported no difference in ANGPTL8 levels between lean
and morbidly obese or between nondiabetic or type 2 diabetic
individuals. In the latter study, ANGPTL8 levels were associated
with an atherogenic lipid profile (Fenzl et al., 2014). Genetic
sequencing of 56,000 individuals revealed a low-frequency
coding DNA sequence variant in ANGPTL8 that was associated
with higher plasma HDL-cholesterol and lower triglycerides but
not with fasting glucose levels (Peloso et al., 2014), once again
confirming the role of ANGPTL8 in lipid metabolism rather than
in regulation of human beta cell function.
In conclusion, the present data do not support a role for
ANGPTL8 in the control of beta cell function or growth. The find-
ings that plasma triglyceride levels are markedly reduced by
Angptl8 deletion and increased following ANGPTL8 overexpres-
sion support the possibility that inhibition of ANGPTL8 repre-
sents a therapeutic strategy for hypertriglyceridemia.
EXPERIMENTAL PROCEDURES
Construct
A cDNA coding for a C-terminal V5 epitope-tagged human ANGPTL8 was
generated by PCR using the following primers: 50-GATATCACTCGAGC
GAGGTCTCCACCATGCCAG-30 and 50-CAATTAGCGGCCGCTCACGTAGAA
TCGAGACCGAGG AGAGGGTTAGGGATAGGCTTACCGGCTGGGAGCGCC
GCTGTGTGGAG-30 and a DNA plasmid clone harboring untagged human
ANGPTL8 (reference sequence NM_018687.6) as the template. The resulting
cDNA was cloned into a mammalian expression vector pRG977. The clone
was confirmed by DNA sequencing. The expression and secretion was evalu-
ated by western blot analysis of CHO cell culture medium using an anti-V5
antibody (Sigma, polyclonal rabbit).
Animals
Angptl8/ mice (75% C57BL/6NTac and 25% 129/SvEvTac background)
were generated by homologous recombination using Regeneron’s VelociGene
technology as previously described (Wang et al., 2013). Mice were housed
(male; one to five per cage) in a controlled environment (12 hr light/dark cycle,
22C ± 1C, 60%–70% humidity) and fed ad libitum with standard chow (Pu-
rina Laboratory Rodent Diet 5001, LabDiet). Somemicewere fed a high-fat diet
(Research Diets, D12492; 60% fat by calories). For all studies reported in this
paper, comparisons were made between wild-type and knock-out littermates.
C57Bl/6 mice (males, 24–28 g; Taconic) were used in the hydrodynamic tail
vein overexpression study. All animal procedures were conducted in compli-
ance with protocols approved by the Regeneron Pharmaceuticals Institutional
Animal Care and Use Committee.
Hydrodynamic DNA Delivery
To establish a baseline, plasma samples were collected from all mice 7 days
prior to hydrodynamic DNA delivery (HDD). On study day 0, mice were sorted
into treatment groups (n = 6–7 per group) based on body weights and their
plasma triglyceride andglucose levels. Themicewere anesthetizedwith isoflur-
ane and injectedwith plasmid at 50mgofDNA in sterile saline via tail vein at 10%
of their body weight. Plasma was collected during the study to assess lipid
levels. Blood glucose was measured from tail tip using Accu-Chek glucometer
(Roche). hANGPTL8 expression in plasma was confirmed by western blotting.
S961 Administration
S961 is an inhibitory peptide (43 aa) with high affinity to the insulin receptor,
was synthesized by Celtek Peptides using published sequence (Scha¨ffer
et al., 2008). S961 or control (PBS) was infused at 20 nMol/week using Alzet
osmotic pump (2002model, Durect) for 13 days. Blood glucose wasmeasured
daily from tail tip using Accu-Chek glucometer (Roche). Plasma was collected
during the study to assess insulin and triglyceride levels. Glucose tolerance
test was performed on day 11 of the study.
Glucose Tolerance Test
Mice were fasted overnight (16 hr) followed by oral gavage of glucose at 2 g/kg
body weight. Blood glucose level was evaluated at 0, 15, 30, 60, and 120 min
postinjection.
Insulin Tolerance Test
Mice were fasted for 4 hr followed by intraperitoneal injection of 0.75 U/kg
(chow-fed) or 2 U/kg (high-fat fed) of human insulin (Eli Lilly). Blood glucose
level was evaluated at 0, 15, 30, 60, and 120 min postinjection.
Serum Chemistry
Serum triglyceride levels were determined using an ADVIA 1800 blood chem-
istry analyzer (Bayer). Circulating insulin level was determined from plasma
samples using a Luminex assay (Millipore).
Analysis of Beta Cell Mass and Area
Pancreas was cassetted in a spread anatomical orientation, embedded in
paraffin, and sectioned to obtain a full footprint. Sections were stained for in-
sulin using polyclonal guinea pig anti-insulin antibody (DAKO; dilution 1:3,000)
using an overnight incubation at 4C. Biotin-conjugated goat anti-guinea pig
IgG (Jackson ImmunoResearch; dilution 1:1,000) was used as secondary anti-
body and incubated for one hour at room temperature followed by detection
with the ABC kit (Vector Laboratories; dilution 1:500). After diaminobenzidine
(DAB)/peroxidase brown visualized reaction (0.4 mg/ml DAB, 0.0003%
H2O2) sections were counterstained with eosin. Beta cell area was measured
using Spectrum software (Indica Labs) and expressed as a percentage of the
total pancreas area of the section. For the insulin receptor antagonist and HDD
studies, we also assessed beta cell mass using point counting morphometry
as described previously (Montan˜a et al., 1993). The data obtained by the
two methods were similar.
Western Blot Analysis
Plasma (1.5 ml) from each animal was resolved by SDS-PAGE using Criterion
TGX 4%–20% precast gel (Bio-Rad) under reducing conditions and trans-
ferred to nitrocellulose membranes. The membranes were probed with an
anti-V5 antibody (Sigma, polyclonal rabbit) and detected with donkey anti-rab-
bit horseradish peroxidase-coupled antibody (Jackson ImmunoResearch) us-
ing an enhanced chemiluminescent detection system.
Data Analysis
Data are expressed as mean ± SEM. Mean values were compared using un-
paired t tests or two-way ANOVA as implemented in the GraphPad Prism
6.0 software (GraphPad Software).SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.cell.2014.09.027.
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